Market capitalization | $375.37m |
Enterprise Value | $136.12m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 0.83 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-123.96m |
Free Cash Flow (TTM) Free Cash Flow | $-109.55m |
Cash position | $324.82m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
7 Analysts have issued a Nkarta Inc forecast:
7 Analysts have issued a Nkarta Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -9.30 -9.30 |
54%
54%
|
|
EBITDA | -115 -115 |
12%
12%
|
EBIT (Operating Income) EBIT | -124 -124 |
9%
9%
|
Net Profit | -108 -108 |
14%
14%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Paul Hastings |
Employees | 150 |
Founded | 2005 |
Website | www.nkartatx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.